Noticias y Actividades de Akari Therapeutics
Ejecutivos
Ver el organigrama con sus 11 ejecutivos principales
Biografías más buscadas en Akari Therapeutics
- Abizer Gaslightwala, President and Chief Executive Officer
- Sandip Patel, Director
- Rob Bazemore, Director
Recientes movimientos de ejecutivos en Akari Therapeutics
- Samir Patel, Chief Executive Officer, abandonará la empresa el 21 de abr.. de 2025 (noticia publicada el 21 de marzo de 2025).
- Abizer Gaslightwala se incorporará a la empresa como President and Chief Executive Officer el 21 de abr.. de 2025 (noticia publicada el 21 de marzo de 2025).
- Samir Patel que ha sido Interim Chief Executive Officer & Director, pasa a ser Chief Executive Officer (noticia publicada el 19 de diciembre de 2024).
Haga clic aquí para ver otros movimientos en Akari Therapeutics
Crear su alerta
para seguir los movimientos de los ejecutivos en Akari Therapeutics.
Biotecnología
Akari Therapeutics tiene 2.339 competidores entre los que se incluyen Eurofins (Luxemburgo), Lonza (Suiza) y Biogen (Estados Unidos).
Popular M&A news in Biotecnología
- Jade Biosciences and Aerovate Therapeutics have announced they will merge (publicado el 30 de abril de 2025)..
- Deepull acaba de anunciar una recaudación de fondos de 50 millones de dólares. (publicado el 29 de abril de 2025).
- Biolinq acaba de anunciar una recaudación de fondos de 100 millones de dólares. (publicado el 23 de abril de 2025).
Otros contactos sugeridos en el sector Biotecnología
Noticias
Últimos comunicados de prensa de Akari Therapeutics
- Akari Therapeutics Narrows Pipeline Focus | Akari Therapeutics
- Akari Therapeutics Announces Positive Results from Recent Pre-Clinical Studies of Investigational PASylated® Nomacopan That Support the Potential to Advance Research Toward IND/IMPD for Clinical Trials in Geographic Atrophy | Akari Therapeutics
- Press Releases | Akari Therapeutics
- Akari Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Pipeline Progress | Akari Therapeutics
- Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase III Part A Clinical Trial of Investigational Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) | Akari Therapeuti
- Press Releases | Akari Therapeutics
- Akari Therapeutics Announces the Appointment of Accomplished Biotech Executive Melissa Bradford-Klug as Chief Operating Officer to Lead Business Development and Company Growth Strategies | Akari Therapeutics
- Akari Therapeutics Presents Results from the CASCADE and CORONET Studies in COVID-19 at the American Thoracic Society (ATS) 2022 Annual Meeting | Akari Therapeutics
- Akari Therapeutics Reports Full Year 2021 Financial Results and Highlights Clinical Progress | Akari Therapeutics
- Akari Therapeutics to Present Results from Compassionate Use of Nomacopan for COVID-19 (CORONET) and Identification of Clinical Deterioration Risk in COVID-19 (CASCADE) at the American Thoracic Society (ATS) 2022 Annual Meeting | Akari Therapeutics
- View more press releases Close
Redes sociales sobre Akari Therapeutics
- Akari Therapeutics en Wikipedia, Google News y Yahoo Finance
- Akari Therapeutics en LinkedIn, Twitter y YouTube
